J. Molner AS submits the Group's unaudited consolidated interim report for H1 2026.
In the first half of 2026, J. Molner took the most significant step yet in the Company's growth through the acquisition, effective June 1, 2026, of a portfolio of FDA-approved products marketed in the United States.
Through this acquisition, the Company more than tripled the number of products it markets in the United States, from four to fourteen, and expanded its channel access into the hospital and specialty pharmacy segments alongside its existing retail pharmacy presence. To support these products, the Company also took on manufacturing relationships with a further seven contract manufacturers, bringing its total manufacturing network, including partners supporting the Company's development pipeline, to fourteen partnerships worldwide.
The acquisition also included rights to certain products not currently marketed which the Company anticipates launching in the first half of 2027. Separately, the Company continued to advance its own development pipeline, spanning several products at various stages of formulation, stability, and regulatory review.
As the transaction closed on June 1, 2026, the financial results presented herein reflect only one month of contribution from the newly acquired portfolio.
The Group's consolidated revenue amounted to EUR 1,964,770 in H1 2026, an increase of 256% compared with H1 2025 (EUR 551,129). EBITDA amounted to EUR 1,730,355 in H1 2026 (H1 2025: EUR −1,381,634). Net profit amounted to EUR 1,441,849 (H1 2025: net loss of EUR 1,411,802).
The unaudited consolidated interim report for the 6-month period ending 30 June 2026 is attached to this announcement.